Alison Taunton-Rigby has assumed the helm as president andchief executive officer of Mitotix Inc., a start-up biotechnologycompany located in Cambridge, Mass. Taunton-Rigby has beena senior executive at Collaborative Research Inc., Biogen Inc.,Vivotech and most recently Genzyme Corp. At Genzyme, shehad overall responsibility for the company's biotherapeuticbusiness.

Mitotix was formed in 1992 to discover, develop andcommercialize therapeutics for proliferative disorders anddiseases, including cancer. The company is developing smallmolecule pharmaceuticals that selectively inhibit cell cycletargets. It was founded by David Beach of Cold Spring HarborLaboratory and Giulio Draetta of the European MolecularBiology Laboratory.

The new president and chief operating officer of InSite VisionInc. is Clifford Orent. Orent had been the chief operating officerof Idec Pharmaceuticals Corp. prior to joining InSite Vision, anAlameda, Calif., company that develops ophthalmicpharmaceutical products for treating ocular diseases.

Matritech Inc. also has a new president, chief operating officerand director. David Corbet had been the Cambridge,'s executive vice president since April. Previously hewas the president of T Cell Diagnostics Inc. Stephen Chubbretains the position of Matritech's chief executive officer andbecomes chairman of the board.

Robert Gerety resigned as vice president-developmentoperations of Biogen Inc. of Cambridge, Mass., and joinedImmuLogic Corp. of Waltham, Mass., as executive vicepresident.

(c) 1997 American Health Consultants. All rights reserved.